A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD

Gérard Socié (1) , Stéphane Vigouroux (2) , Ibrahim Yakoub-Agha (3) , Jacques-Olivier Bay (4) , Sabine Furst (5) , Karin Bilger (6) , Felipe Suarez (7) , Mauricette Michallet (8) , Dominique Bron (9) , Philippe Gard , Zakaria Medeghri , Philippe Lehert (10) , Chinglin Lai , Tim Corn , Jean-Paul Vernant (11)

1 Service greffe de moelle osseuse
2 Dpt hématologie [CHU Bordeaux]
3 LIRIC - Lille Inflammation Research International Center - U 995
4 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias
5 IPC - Institut Paoli-Calmettes
6 Département d'Oncologie et Hématologie [Strasbourg]
7 Service d'immuno-hématologie pédiatrique [CHU Necker]
8 Service d'hématologie [Hôpital Edouard Herriot - HCL]
9 Service Hématologie
10 Faculté d'économie
11 CHU Pitié-Salpêtrière [AP-HP]

Domaines: Hématologie

Gérard Socié, Stéphane Vigouroux, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Sabine Furst, et al.. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood, 2017, 129 (5), pp.643 - 649. ⟨10.1182/blood-2016-09-738625⟩. ⟨hal-01655868⟩